HB 263, NOTICE OF DRUG PRICE INCREASE, (Winder, M)

Anticipated Fiscal Impact:

No Additional Costs to State Health Insurance Pool

HB 263 requires drug manufacturers to report and justify price increases over 10% a year for any drug. Manufacturers would need to report these increases to PEHP and other health insurers, as well as the state Department of Insurance who would publish the information. We don’t anticipate any additional costs to the State Health Insurance Risk Pool as a result of HB 263 and recognize that transparency may help discourage drug price increases.